Loading clinical trials...

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

An 8-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Pilot Study of Pagoclone in Patients With Persistent Developmental Stuttering Followed by a 52-week Open-Label Extension.

NCT00239915•Pharmacology Research Institute

View on ClinicalTrials.gov

Summary

This is a research study of the investigational drug, Pagoclone, in the treatment of persistent developmental stuttering (PDS), which includes frequent repetitions or prolongations of sounds or syllables or words, or frequent hesitations or pauses that disrupt the flow of speech. Pagoclone is an investigational drug, so it is not approved by the United States Food and Drug Administration.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•PDS defined as DSM-IV-TR criteria
•Symptoms starting before age 8
•Total overall score of 18-36 on the SSI-3
•English speaking, with an 8th grade education
•Able to understand and cooperate with study requirements with assistance
•Not pregnant or breastfeeding
•Able to provide consent

Exclusion Criteria

•No diagnoses of other CNS/Mental health disorders in the last 6 months
•No use of psychotropic medication or other medication for stuttering within 4 weeks prior to screening
•No use of non-medicinal stuttering treatments for 5 months prior to the study
•No use of illicit drugs or opiates of any kind

Locations (1)

Pharmacology Research Institute

Riverside, California, United States

Key Dates

Start Date

April 1, 2005

Completion Date

December 1, 2006

Last Updated

May 9, 2012

Conditions

Persistent Developmental Stuttering

Interventions

Pagoclone

DRUG

Explorative Study for Treating Persistent Developmental Stuttering With Ramipril

NCT04173949

Persistent Developmental Stuttering

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions